Use of Markov modeling for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients

Transplantation Proceedings

Volumn 28, Issue 4, 1996, Pages 2214-2217

  Lewis, R L ^a   Canafax, D M ^a   Pettit, K G ^a   DiCesare, J ^a   Kaniecki, D J ^a   Arnold, R J ^a   Roberts, M S ^a   Roth, D ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; PREDNISONE;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG FORMULATION; EMULSION; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STATISTICAL MODEL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; CADAVER; COHORT STUDIES; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; CYCLOSPORINE; DOSAGE FORMS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LENGTH OF STAY; MARKOV CHAINS; TISSUE DONORS; UNITED STATES;

EID: 0029788067     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (0)